Frakturen, Rückenschmerzen, Lebensqualität und Compliance unter einer Teriparatid-Therapie bei Patientinnen mit postmenopausaler Osteoporose in Deutschland

S. Scharla; H. Oertel; H. Petto; F. Jakob

doi:10.1055/s-0038-1630119

Osteologie, Table of Contents

Osteologie 2013; 22(03): 214-222
DOI: 10.1055/s-0038-1630119

Original and review articles

Schattauer GmbH

Frakturen, Rückenschmerzen, Lebensqualität und Compliance unter einer Teriparatid-Therapie bei Patientinnen mit postmenopausaler Osteoporose in Deutschland

Subgruppen-Analyse der prospektiven europäischen Langzeit-Anwendungsbeobachtung EFOS1 (European Forsteo® Observational Study)Fractures, back pain, quality of life, and compliance in German postmenopausal patients with osteoporosis treated with teriparatideSubgroup analysis of the European Forsteo® Observational Study (EFOS)

S. Scharla

¹Praxis Innere Medizin und Endokrinologie/Diabetologie, Bad Reichenhall, Deutschland, und Medizinische Fakultät Ludwig-Maximilians-Universität München, Deutschland

,

H. Oertel

²Lilly Deutschland GmbH, Medical Department, Bad Homburg, Deutschland

,

H. Petto

³Lilly Österreich GmbH, Wien, Österreich

,

F. Jakob

⁴Universität Würzburg, Experimentelle und klinische Osteologie, Orthopädische Klinik König-Ludwig-Haus, Würzburg, Deutschland

› Author Affiliations

Abstract

Zusammenfassung

Ziel: Primäres Ziel der Beobachtungsstudie EFOS war die Erfassung der Inzidenz von klinischen vertebralen und nichtvertebralen Frakturen bei postmenopausalen Frauen mit Osteo porose während einer 18-monatigen Teriparatid-Behandlung und einer 18-monatigen Nachbeobachtung. Weiterhin wurden gesundheitsbezogene Lebensqualität (EQ-5D und EQ-visuelle Analogskala [VAS]) und Rückenschmerzen (Häufigkeit, Schweregrad, Aktivitätseinschränkungen, VAS) evaluiert.

Methode: Veränderungen der Frakturinzidenz in jeweils 6-Monats-Intervallen wurden mittels logistischer Regression mit wiederholten Messungen und Veränderungen der VASWerte mit einem gemischten Modell für wiederholte Messungen analysiert.

Ergebnisse: Von 385 deutschen Patientinnen erlitten 44 (11,4 %) im Studienverlauf 52 Frakturen (17 vertebrale, 35 nicht-vertebrale). Die Inzidenz von Frakturen wurde signifikant reduziert (ab Monat 24 bis < 30 vs. Monat 0 bis < 6). Die sekundären Variablen verbesserten sich im Studienverlauf. Die Veränderungen waren dabei gegenüber dem Studienbeginn zu allen Zeitpunkten signifikant.

Schlussfolgerung: Die Befunde sind bei diesem nicht kontrollierten Studiendesign mit den entsprechenden Einschränkungen zu werten.

Summary

Aim: The primary objective of the European Forsteo Observational Study (EFOS) was to analyze the incidence of clinical vertebral and non-vertebral fractures in postmenopausal women with osteoporosis treated with teriparatide for up to 18 months. The active treatment period was followed by an 18-month follow-up period, where up to 44.2 % of patients received other osteoporosis medications. In addition to the incidence of fractures, health related quality of life (EQ-5D and EQ-visual analogue scale [VAS]), back pain (incidence and severity of back pain, activity limitations due to back pain, VAS) and bone mineral density (T-score) were evaluated.

Methods: Changes in the odds of fracture were analyzed in 6-month intervals using logistic regression with repeated measures and the changes in VAS scores were analyzed using a mixed model for repeated measures. Improvement/worsening from baseline in EQ-5D domains and in frequency and severity of patients with back pain were analyzed with the sign test. A total of 412 German patients participated in the EFOS study and 385 patients had evaluable data.

Results: The median duration of teriparatide treatment was 542 days (Q1 = 515 days, Q3 = 562 days). The most important reasons for discontinuing teriparatide were patient's decision and adverse events. A total of 44 patients (11.4 %) experienced 52 fractures (17 vertebral, 35 non-vertebral fractures) during Rückenthe study. The odds of fractures were significantly reduced (from months 24 to < 30 onwards versus months 0 to < 6; odds ratio interval 24 to < 30 months versus 0 to < 6 months: 0.20 [95 % confidence interval, CI 0.05, 0.85], p-value 0.029; odds ratio interval 30 to < 36 months versus 0 to < 6 months: 0.11 [95 % CI 0.01, 0.83], p-value 0.032). The frequency and severity of back pain was reduced and the health related quality of life improved in all 5 domains (change from baseline to all time points statistically significant, p < 0.001).

Conclusion: The results should be carefully interpreted in context of the observational study design.

Schlüsselwörter

Osteoporose - Teriparatid - Beobachtungs-studie - Subgruppenanalyse Deutschland

Keywords

Osteoporosis - teriparatide - observational study - subgroup analysis Germany

Full Text

References

Literatur
1 Steinleitner WE, Thuro HC, Schöffel D. Schmerzen bei Osteoporose – die schmerzhafte osteoporotische Wirbelkörperfraktur. Osteologie 2008; 17: 195-199.
2 Cooper C, Jakob F, Chinn C. et al. Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int 2008; 19: 493-501.
3 Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767.
4 Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005; 16: 229-238.
5 Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359: 2018-2026.
6 Jiang Y, Zhao JJ, Mitlak BH. et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18: 1932-1941.
7 Neer RM, Arnaud CD, Zanchetta JR. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441.
8 Saag KG, Shane E, Boonen S. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-2039.
9 Rajzbaum G, Jakob F, Karras D. et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008; 24: 377-384.
10 Langdahl BL, Rajzbaum G, Jakob F. et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009; 85: 484-493.
11 Fahrleitner-Pammer A, Langdahl BL, Marin F. et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 2011; 22: 2709-2719.
12 Jakob F, Oertel H, Langdahl B. et al. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol 2012; 166: 87-97.
13 EuroQuol Group. EuroQuoL: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
14 Abelson A, Ringe JD, Gold DT. et al. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int 2010; 21: 1021-1029.
15 Genant HK, Halse J, Briney WG. et al. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 2005; 21: 1027-1034.
16 Hadji P, Zanchetta JR, Russo L. et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 2012; 23: 2141-2150.